- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00962598
The Role Of Omega-3 Fatty Acids In Adolescent Depression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study rests on a confluence of findings showing that: 1) Major depressive disorder (MDD), is a major public health concern that often emerges in adolescence; which entails 2) pathophysiological abnormalities in fronto-striatal structures resulting in death and atrophy of glia and neurons; 3) omega-3 fatty acids (FA) effects on brain function in adolescent MDD can be assessed by proton magnetic resonance spectroscopy (1H MRS); and, 4) it is critical that commonly used complementary and alternative medicines such as omega-3FA that have face validity be tested for their neurobiological effect in MDD.
Using 1H MRSI, this study examines the effects of Omega-3FA on striatal and anterior cingulate cortex (ACC) concentrations of the neurocellular biomarkers total choline (tCho), total creatine (tCr), and γ-aminobutyric acid (GABA, ACC only) in adolescent MDD. Hypotheses are: 1) relative to placebo, omega-3FA treatment will result in significant reductions of striatal and ACC tCho and tCr concentrations, and increased ACC GABA; 2: Regardless of treatment condition (placebo or Omega-3FA), MDD adolescents who are improved at the end of 10-week treatment will exhibit a significant decrease in striatal and ACC tCho and tCr concentrations, and increases in ACC GABA relative to unimproved adolescents.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 12 to 19 years old (inclusive) of both sexes and all ethnic/racial groups.
- DSM-IV-TR criteria for MDD
- MDD Duration of at least 8 weeks and a severity score of at least 40 on the CDRS-R.
- Age at first onset MDD of at least 12 years.
- No significant medical or neurological disorder
- For female subjects, negative pregnancy test at time of enrollment.
- Female subjects who are sexually active and not using a method of birth control will be excluded. Use of hormonal contraceptives (such as prescribed "birth control pills" or a prescribed birth control implant) is not exclusionary.
- Subjects must be able to swallow capsules.
- A minimum IQ of 80 will be required.
Exclusion Criteria:
- Current or Past DSM-IV-TR diagnoses of bipolar disorder, schizophrenia, psychosis, autism/pervasive developmental disorder (PDD), and Tourette's disorder (TD).
- Current diagnosis of eating disorder, panic disorder, obsessive-compulsive disorder (OCD), post traumatic stress disorder (PTSD), conduct disorder, and substance related disorders other than nicotine.
- Current suicidal ideation with intent or plan, or who may pose a danger to themselves.
- Current antidepressant treatment will be excluded. Past antidepressant treatment will not be exclusionary, so long as patients are off antidepressant medication for 60 days prior to study entry. No individual will be advised to terminate ongoing treatment.
- Certain short half-life medications, such as vitamins that contain unidentified ingredients, St. Johns Wort, S-adenosyl Methionine (SAM), clonidine, and some over-the-counter medications.
- A minimum of 90 days off of treatment with long half life medications, such as neuroleptics, prior to study entry is required. Stimulant medication treatment for ADHD will not be exclusionary.
- If adolescents have been in psychotherapy prior to their entry in the study, they will be allowed to continue with the treatment. However, psychotherapy cannot be initiated at the time of study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Corn Oil
The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.
|
The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment.
Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
|
Experimental: Omega-3 Fatty Acids
The initial dose will be 1.2g/d.
This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.
|
The study medication will consist of combined EPA/DHA with a ratio of 2:1.
Dosage will be titrated based on clinical response and side effects.
The initial dose will be 1.2g/d.
This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d.
Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose.
The total duration of the intervention will be 10 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ACC Glx/Water
Time Frame: baseline and 10-weeks
|
The data reflects the ratio of Glutamine-Glutamate and water in the brain (ratio divided by 10000 for analysis purposes).
Glutamate is a precursor to Glutamine, an amino acid which functions as an excitatory neurotransmitter in the human brain.
|
baseline and 10-weeks
|
ACC GABA/Water
Time Frame: baseline and 10-weeks
|
The ratio of gamma-Aminobutyric acid (GABA) and water in the brain (ratio divided by 10000 for analysis purposes), that was observed in MR Spectroscopy.
GABA, an amino acid produced by cells of the central nervous system, is an inhibitory neurotransmitter, prominent in the human brain.
|
baseline and 10-weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Vilma Gabbay, M.D., Icahn School of Medicine at Mount Sinai
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 12-1321
- R21AT004576-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Corn oil
-
St. Luke's-Roosevelt Hospital CenterUSDA Beltsville Human Nutrition Research Center; Prosperity Organic FoodsCompletedChildhood ObesityUnited States
-
University GhentJimma University; Nutricia Research Fundation; VLIR Institutional University... and other collaboratorsCompletedChild MalnutritionEthiopia
-
University of RochesterGlaxoSmithKline; Albany College of Pharmacy and Health SciencesTerminated
-
Laval UniversityCanadian Institutes of Health Research (CIHR)Completed
-
Universiti Sains MalaysiaCompleted
-
Columbia UniversityUnited States Department of Agriculture (USDA)CompletedObesity | Overweight | Pediatric ObesityUnited States
-
National University Hospital, SingaporeWilmar InternationalEnrolling by invitationNAFLD | Non-Alcoholic Fatty Liver Disease | Non-Alcoholic SteatohepatitisSingapore
-
Gottfried Wilhelm Leibniz Universität HannoverCompleted
-
Vejle HospitalRecruitingColorectal Cancer | Peripheral NeuropathyDenmark